IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

Core Insights - IMUNON, Inc. is advancing its IMNN-001 program, currently in the OVATION 3 pivotal Phase 3 trial for advanced ovarian cancer, with new data from the Phase 2 OVATION 2 trial to be presented at the SITC Annual Meeting [1][3] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms for effective responses against various diseases [10][11] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, having completed multiple clinical trials including the Phase 2 OVATION 2 and currently conducting the Phase 3 OVATION 3 trial [11] IMNN-001 Therapy Details - IMNN-001 is based on IMUNON's TheraPlas® technology, utilizing an IL-12 DNA plasmid vector in a nanoparticle delivery system to induce strong anti-cancer immunity [2][8] - The therapy has shown clinically effective responses in advanced ovarian cancer, improving both progression-free survival (PFS) and overall survival (OS) when combined with standard chemotherapy [2][4] Clinical Trial Insights - The OVATION 3 trial is designed with at least 95% statistical power for the primary endpoint of overall survival, including two planned interim analyses for potential accelerated FDA submission [5][6] - The OVATION 2 study demonstrated a median OS increase of 13 months and a median PFS increase of 3 months for the IMNN-001 treatment arm compared to standard care [5][7] Presentation and Data Sharing - Positive translational data from the OVATION 2 study was previously presented at the AACR Special Conference, highlighting the safety profile and efficacy of IMNN-001 [3][4] - The upcoming SITC presentation will focus on how IMNN-001 can convert the tumor microenvironment from "cold" to "hot," enhancing immune response in newly diagnosed epithelial ovarian cancer [3]